Skip over navigation
Directory
Directory Search
Jobs
Job Search
Post a Job
Patient
Patient Resources
Drug Development
History
Genealogy
Toons & Teasers
About
Advertising
Home
Quick Links
Directory
Job Search
Toons & Teasers
Advertising
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Industry News
Search Articles:
Celldex's METRIC study in metastatic triple-negative breast cancer does not meet endpoint
Celldex reported the Company's randomized, Phase 2b METRIC Study of glembatumumab vedotin versus Xeloda® (capecitabine) in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.
April 16, 2018
More...
Email This Page
to a Friend
Print This
Page